Table 1. Selected ongoing clinical trials evaluating PARP inhibitor monotherapy.
| Tumor type/eligibility | Experimental Agent | Molecular Target | Randomized | Phase | NCT number |
|---|---|---|---|---|---|
| Solid tumors (metastatic) | BMN 673 (talazoparib) | Deleterious BRCA1/2 | No | Phase I | NCT01989546 |
| Prostate cancer (Pre-surgery)π | olaparib vs olaparib+degarilix intermediate/high risk disease |
none | Yes | Phase I | NCT02324998 |
| Solid tumors (advanced, unresectable, metastatic) | veliparib vs veliparib+mitomycinC | Deficient Fanconi Anemia pathway on FATSI | Yes | Phase I | NCT01017640 |
| Solid tumor Expansion: ovarian cancer | rucaparib | Expansion cohort only: deleterious gBRCA1/2m | No | Phase I/II | NCT01482715 |
| Breast cancer B (locally advanced/metastatic) | BMN 673 (talazoparib) ABRAZO study |
gBRCA1/2m | No | Phase II | NCT02034916 |
| Breast cancer (metastatic /recurrent) | BMN 673 (talazoparib) |
BRCA1/2 WT, Triple neg or HER2 neg HR deficiency, germ/som MT* |
No | Phase II | NCT02401347 |
| Advanced malignancy | BMN 673 (talazoparib) | multipleα | No | Phase II | NCT02286687 |
| Non-small cell lung cancer (chemo-responsive) | Olaparib vs placebo | None | Yes | Phase II | NCT01788332 |
| Endometrial cancer (inoperable, advanced) | BMN 673 (talazoparib) PANDA study |
Retrospective PTEN, MSI and MRE11 analysis | No | Phase II | NCT02127151 |
| Ovarian/PP/Fallopian X (platinum-sensitive, relapsed) | Rucaparib ARIEL2 study |
Tumor HRD status | No | Phase II | NCT01891344 |
| Ovarian cancer (≥3 prior lines Rx)∞ | niraparib | None | No | Phase II | NCT02354586 |
| Breast Cancer (stage III or IV) | ABT-888 (veliparib)+/-carboplatin | Deleterious gBRCA1/2m | Yes | Phase II | NCT01149083 |
| Ovarian cancer (received prior PARPi) | BMN 673 (talazoparib) | Deleterious gBRCA1/2m | No | Phase II | NCT02326844 |
| Ovarian/PP/Fallopian (After CR/PR to platinum) | olaparib vs placebo | Deleterious BRCA1/2m | Yes | Phase III | NCT01874353 |
| Ovarian/PP/Fallopian (After CR/PR to platinum, maintenance) | rucaparib vs placebo ARIEL3 study |
Tumor HRD status | Yes | Phase III | NCT01968213 |
| Ovarian cancer FIGO III-IV (after first-line platinum) | olaparib vs placebo | Deleterious BRCA1/2m | Yes | Phase III | NCT01844986 |
| Breast cancer (metastatic/recurrent) | talazoparib vs Physician's choice EMBRACA studyϕ |
gBRCA1/2m | Yes | Phase III | NCT01945775 |
| Breast cancer** (metastatic) | olaparib vs Physician's choice OLYMPIAD study |
gBRCA1/2m | Yes | Phase III | NCT02000622 |
| Breast cancerɤ (HER2 negative) | niraparib vs physician's choice | gBRCA1/2m | Yes | Phase III | NCT01905592 |